Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

CSPC Pharmaceutical Group stock

1093.HK
HK1093012172
548183

Price

4.72
Today +/-
+0.00
Today %
+0.43 %

CSPC Pharmaceutical Group stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the CSPC Pharmaceutical Group stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the CSPC Pharmaceutical Group stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the CSPC Pharmaceutical Group stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze CSPC Pharmaceutical Group's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

CSPC Pharmaceutical Group Stock Price History

DateCSPC Pharmaceutical Group Price
11/29/20244.72 undefined
11/28/20244.70 undefined
11/27/20244.82 undefined
11/26/20244.70 undefined
11/25/20244.73 undefined
11/22/20244.74 undefined
11/21/20244.83 undefined
11/20/20244.85 undefined
11/19/20244.82 undefined
11/18/20244.76 undefined
11/15/20244.76 undefined
11/14/20244.82 undefined
11/13/20244.88 undefined
11/12/20244.97 undefined
11/11/20244.96 undefined
11/8/20244.94 undefined
11/7/20245.00 undefined
11/6/20244.92 undefined
11/5/20245.00 undefined
11/4/20244.79 undefined
11/1/20244.83 undefined

CSPC Pharmaceutical Group Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into CSPC Pharmaceutical Group, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by CSPC Pharmaceutical Group from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects CSPC Pharmaceutical Group’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of CSPC Pharmaceutical Group. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into CSPC Pharmaceutical Group’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing CSPC Pharmaceutical Group’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on CSPC Pharmaceutical Group’s growth potential.

CSPC Pharmaceutical Group Revenue, EBIT and net profit per share

DateCSPC Pharmaceutical Group RevenueCSPC Pharmaceutical Group EBITCSPC Pharmaceutical Group Net Income
2029e38.36 B undefined7.66 B undefined6.31 B undefined
2028e36.93 B undefined7.4 B undefined6.18 B undefined
2027e35.37 B undefined7.12 B undefined5.95 B undefined
2026e36.54 B undefined7.39 B undefined6.81 B undefined
2025e34.52 B undefined6.97 B undefined6.25 B undefined
2024e33.11 B undefined6.97 B undefined6.13 B undefined
202331.45 B undefined7.35 B undefined5.87 B undefined
202230.94 B undefined7.19 B undefined6.09 B undefined
202127.87 B undefined6.5 B undefined5.61 B undefined
202024.94 B undefined5.56 B undefined5.16 B undefined
201922.1 B undefined4.65 B undefined3.71 B undefined
201817.72 B undefined3.73 B undefined3.08 B undefined
201713.85 B undefined3.14 B undefined2.48 B undefined
201611.08 B undefined2.38 B undefined1.88 B undefined
20159.5 B undefined1.81 B undefined1.39 B undefined
20149.84 B undefined1.5 B undefined1.14 B undefined
20137.89 B undefined948 M undefined771 M undefined
20123.37 B undefined613 M undefined1.76 B undefined
20116.13 B undefined312 M undefined194 M undefined
20106.77 B undefined950 M undefined655 M undefined
20096.2 B undefined1.04 B undefined855 M undefined
20086.1 B undefined1.09 B undefined839 M undefined
20074.86 B undefined669 M undefined465 M undefined
20063.63 B undefined103 M undefined16 M undefined
20053.36 B undefined230 M undefined165 M undefined
20042.6 B undefined290 M undefined260 M undefined

CSPC Pharmaceutical Group Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (B)DOCUMENTS
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0.640.881.061.241.732.642.63.363.634.866.16.26.776.133.377.899.849.511.0813.8517.7222.124.9427.8730.9431.4533.1134.5236.5435.3736.9338.36
-37.5220.6617.3139.1152.75-1.1829.078.0333.8525.431.649.33-9.57-44.96133.8424.84-3.4616.5625.0227.9324.7612.8411.7211.021.665.284.265.84-3.204.433.86
32.3429.5724.8828.2330.9637.3125.7321.7217.3230.8233.4032.2529.2420.0843.5331.4938.2345.8251.0160.4466.2571.9974.9175.8571.9470.5166.9764.2460.7062.7060.0457.81
0.210.260.260.350.530.980.670.730.631.52.0421.981.231.472.483.764.355.658.3711.7415.9118.6921.1422.2622.18000000
0.110.150.090.150.240.540.260.170.020.470.840.860.660.191.760.771.141.391.882.483.083.715.165.616.095.876.136.256.815.956.186.31
-40.74-44.0875.2962.42121.49-51.49-36.54-90.302,806.2580.431.91-23.39-70.38806.70-56.1747.7321.8635.5231.9024.1420.5838.918.658.67-3.584.431.838.97-12.553.901.97
--------------------------------
--------------------------------
1.051.141.261.261.41.541.541.541.541.541.541.541.541.534.585.885.9711.4411.5311.711.9811.9611.9611.9511.9211.87000000
--------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The CSPC Pharmaceutical Group Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the CSPC Pharmaceutical Group is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (B)INVENTORIES (B)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (B)PROVISIONS (M)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                   
0.220.220.130.190.340.50.530.490.390.410.991.270.930.841.170.931.321.922.95.876.635.968.7910.713.813.07
0.310.480.490.470.540.470.380.410.50.630.650.760.941.031.561.441.611.431.391.722.132.42.543.414.16.03
0.040.030.060.170.130.110.180.290.190.370.450.851.021.030.880.971.121.31.331.781.52.052.23.142.733.81
0.080.130.150.160.290.310.480.790.690.871.170.861.021.331.631.451.621.521.732.63.052.541.862.482.553.14
000003285755514334243190215.8217.35198.46246.26500.57753.55520.86604.36770.38697.03
0.650.850.830.981.311.431.581.981.772.283.253.83.954.265.474.985.896.387.5512.2113.813.715.9220.3423.9626.74
0.821.11.131.241.641.853.213.313.253.423.333.563.693.954.933.874.544.294.855.976.699.288.939.5610.9811.64
0.020.020.020.020.020.020.030.030.020.020.030.030.030.040.030.020.070.020.150.380.91.493.183.363.784.66
054322100000000000000150.43757.33253.9500
0.040.090.080.090.090.060.070.060.050.060.080.140.180.210.020.10.10.080.070.090.811.140.510.471.912.2
00006463595856949413313213383100112.3999.58100.11109.03140.75188.96149.98149.98234.9234.9
84620014960163148184177227256284478461479.38422.46496.78531.8874.85378.22622.83612.87909.6805.85
0.961.221.241.361.822.163.433.623.523.773.74.094.294.625.544.555.34.915.677.089.4112.6214.1514.4117.8119.54
1.612.072.072.353.133.585.015.65.296.056.967.898.248.8811.019.5311.1811.2913.2219.2923.2226.3230.0734.7441.7746.28
                                                   
0.110.130.130.130.160.160.160.160.150.140.140.140.130.120.220.448.828.29.4711.5710.910.910.910.910.910.9
0.650.890.890.891.171.191.191.161.121.050.990.980.950.912.666.830.040.040.050.050.050.050.050.050.20.39
0.050.150.230.380.580.911.051.191.161.532.192.7932.75-2.73-2.09-1.64-0.630.472.34.067.411.5215.1519.1622.22
00000000.070.210.420.650.630.791.015.140.640.03-0.32-0.93-0.2-0-0.02-0.04-0.030.020
0000000000010-1000002.8553.42237.130000
0.811.171.251.41.92.262.412.592.653.143.964.544.874.785.35.827.267.299.0513.7215.0518.5622.4326.0730.2833.52
0.290.340.280.380.490.540.490.520.420.470.580.620.660.920.950.770.880.9611.341.621.111.21.481.72.47
00000000000000174110118.4493.38175.77311.59445.83371.34385.88519.26728.17841.8
0.040.050.0100.020.020.50.510.380.670.790.830.890.791.851.391.471.481.682.685.114.664.495.196.236.27
000044319413420224168230314374588587213204.13000000000
0.110.340.330.320.580.170.270.360.760.910.50.780.270.711.460.520.560.380.80.830.070.10.220.040.30.6
0.440.720.620.71.131.051.671.811.772.222.12.532.23.025.0233.242.913.665.167.256.246.37.238.9610.18
0.360.170.190.230.090.260.931.190.860.670.810.631.020.930.40.530.540.840.220.0500.090.090.060.290.11
000000000014313838382626.6438.6461.67117.86237.92304.43320.44381.48611.99574.84
0000000000000011941104.03154.9156.7164.77202.3168.66253.97250.2270.92399.68
0.360.170.190.230.090.260.931.190.860.670.820.661.060.970.560.60.671.040.430.340.440.560.670.691.171.08
0.790.890.810.931.221.312.632.632.892.923.193.263.985.583.593.913.944.095.497.696.86.977.9110.1311.26
1.62.062.062.343.123.5855.595.286.036.887.748.138.7710.879.4111.1711.2313.1419.2222.7425.3629.433.9940.4144.78
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of CSPC Pharmaceutical Group provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand CSPC Pharmaceutical Group's financial health and stability.

Assets

CSPC Pharmaceutical Group's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that CSPC Pharmaceutical Group must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of CSPC Pharmaceutical Group after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into CSPC Pharmaceutical Group's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
0.120.150.110.180.320.660.290.1600.510.990.990.840.261.870.991.481.772.363.13.794.636.396.857.58
0.040.070.10.110.130.160.20.280.340.410.420.440.490.50.150.510.540.490.510.630.610.690.810.861.05
0000000000000000000000000
16-190-172-80-9528945-327-205-205-209-98-569-537-359-686-396-409-269-781-479-1,384619-2,529-536
414533320192911001621585011278-1,258-165213012-2-131-149-1,077-545-464
36343127292733789710997615560455247473625743210721
0.0100.010.040.030.10.020.0100.020.070.130.190.10.090.180.270.320.430.520.640.871.061.141.33
0.180.050.090.250.371.120.530.20.240.881.351.380.880.30.410.651.651.882.612.943.83.786.744.647.63
-140-280-145-319-330-345-1,173-510-353-624-368-632-756-768-163-513-744-695-1,062-1,092-2,156-2,122-1,576-1,758-2,722
-136-235-144-294-306-539-1,147-483-335-773-393-891-717-744212494-681-596-1,192-2,944-3,627-2,457-2,129-637-6,795
00.0500.030.02-0.190.030.030.02-0.15-0.03-0.260.040.020.381.010.060.1-0.13-1.85-1.47-0.33-0.551.12-4.07
0000000000000000000000000
-174912108110-2337583788225-21396-58374-62-751-57220-253-172-782-11276-222-135
00.2000.030.020000-0.0100-0.020.690000.52.11-0.081.120-0.26-0.01
-0.050.22-0.030.110.09-0.420.640.24-0.02-0.08-0.37-0.21-0.50.360.31-1.37-0.68-0.51-0.411.46-0.15-1.55-1.47-2.2-1.9
00.010-00-00-0.08-0.1-0.11-0.08-0.03-0.120.150.01-0.32-0.19-0.23-0.070.171.5-1.59-0.02-0.020.34
-29-33-430-47-210-114-5700-68-270-321-149-332-303-432-494-582-650-782-965-1,527-1,690-2,096
-00.03-0.080.060.150.160.03-0.03-0.090.050.610.28-0.3-0.050.93-0.210.260.70.841.730.02-0.223.141.8-1.06
39.5-232.2-54.3-7337.5775.5-639.8-313.6-117252.3984.8749120.9-470.5241.5132.7908.191,188.421,549.621,852.521,638.441,661.235,1632,878.184,904.37
0000000000000000000000000

CSPC Pharmaceutical Group stock margins

The CSPC Pharmaceutical Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of CSPC Pharmaceutical Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for CSPC Pharmaceutical Group.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the CSPC Pharmaceutical Group's sales revenue. A higher gross margin percentage indicates that the CSPC Pharmaceutical Group retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the CSPC Pharmaceutical Group's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the CSPC Pharmaceutical Group's total revenue generated. When comparing the revenue margin year over year, investors can gauge the CSPC Pharmaceutical Group's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the CSPC Pharmaceutical Group. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the CSPC Pharmaceutical Group's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

CSPC Pharmaceutical Group Margin History

CSPC Pharmaceutical Group Gross marginCSPC Pharmaceutical Group Profit marginCSPC Pharmaceutical Group EBIT marginCSPC Pharmaceutical Group Profit margin
2029e70.51 %19.97 %16.44 %
2028e70.51 %20.03 %16.74 %
2027e70.51 %20.12 %16.83 %
2026e70.51 %20.22 %18.63 %
2025e70.51 %20.2 %18.09 %
2024e70.51 %21.05 %18.52 %
202370.51 %23.37 %18.68 %
202271.94 %23.25 %19.69 %
202175.84 %23.34 %20.11 %
202074.91 %22.3 %20.69 %
201971.98 %21.03 %16.8 %
201866.25 %21.03 %17.39 %
201760.44 %22.65 %17.92 %
201651 %21.48 %16.98 %
201545.82 %19 %14.62 %
201438.22 %15.25 %11.58 %
201331.49 %12.02 %9.78 %
201243.53 %18.18 %52.16 %
201120.08 %5.09 %3.17 %
201029.24 %14.02 %9.67 %
200932.25 %16.82 %13.8 %
200833.4 %17.83 %13.76 %
200730.82 %13.77 %9.57 %
200617.32 %2.84 %0.44 %
200521.72 %6.84 %4.91 %
200425.73 %11.14 %9.98 %

CSPC Pharmaceutical Group Stock Sales Revenue, EBIT, Earnings per Share

The CSPC Pharmaceutical Group earnings per share therefore indicates how much revenue CSPC Pharmaceutical Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue CSPC Pharmaceutical Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates CSPC Pharmaceutical Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of CSPC Pharmaceutical Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating CSPC Pharmaceutical Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

CSPC Pharmaceutical Group Revenue, EBIT and net profit per share

DateCSPC Pharmaceutical Group Sales per ShareCSPC Pharmaceutical Group EBIT per shareCSPC Pharmaceutical Group Earnings per Share
2029e3.29 undefined0 undefined0.54 undefined
2028e3.17 undefined0 undefined0.53 undefined
2027e3.03 undefined0 undefined0.51 undefined
2026e3.13 undefined0 undefined0.58 undefined
2025e2.96 undefined0 undefined0.54 undefined
2024e2.84 undefined0 undefined0.53 undefined
20232.65 undefined0.62 undefined0.49 undefined
20222.6 undefined0.6 undefined0.51 undefined
20212.33 undefined0.54 undefined0.47 undefined
20202.09 undefined0.47 undefined0.43 undefined
20191.85 undefined0.39 undefined0.31 undefined
20181.48 undefined0.31 undefined0.26 undefined
20171.18 undefined0.27 undefined0.21 undefined
20160.96 undefined0.21 undefined0.16 undefined
20150.83 undefined0.16 undefined0.12 undefined
20141.65 undefined0.25 undefined0.19 undefined
20131.34 undefined0.16 undefined0.13 undefined
20120.74 undefined0.13 undefined0.38 undefined
20114 undefined0.2 undefined0.13 undefined
20104.41 undefined0.62 undefined0.43 undefined
20094.04 undefined0.68 undefined0.56 undefined
20083.96 undefined0.71 undefined0.55 undefined
20073.16 undefined0.43 undefined0.3 undefined
20062.36 undefined0.07 undefined0.01 undefined
20052.19 undefined0.15 undefined0.11 undefined
20041.69 undefined0.19 undefined0.17 undefined

CSPC Pharmaceutical Group business model

CSPC Pharmaceutical Group Ltd. is a leading pharmaceutical company in China. It was founded in 1997 and specializes in the manufacturing of pharmaceutical raw materials, intermediates, and finished drugs. The company's product range covers various therapy areas and provides a variety of medications for patients worldwide. The company's business model is based on research, development, and production of pharmaceutical products for the mass market. In 2019, CSPC Pharmaceutical achieved a revenue of 9.9 billion USD. The company's products are represented in 24 countries worldwide and aim to improve people's lives through innovations in the healthcare sector. CSPC Pharmaceutical has various divisions, including its sister company CSPC Zhongqi Pharmaceutical Technology Co. Ltd., which specializes in innovative technologies for drug manufacturing. Other divisions include CSPC Weisheng Pharmaceutical Co. Ltd. for marketing and distribution in China, as well as CSPC Ouyi Pharmaceutical Co. Ltd. for the production of traditional Chinese medicines. The product range of CSPC Pharmaceutical is diverse and offers medications for various application areas. This includes cancer therapy with products such as Anastrozole tablets and Vinorelbine injection solution. In the field of cardiovascular diseases, CSPC Pharmaceutical offers Metoprolol Succinate tablets. Additionally, the company provides products for the treatment of pain and inflammation, such as Ibuprofen suspension and generic versions of Celecoxib. Another focus of the company is the research and production of antibiotics, which are important medications in the treatment of bacterial infections. CSPC Pharmaceutical produces a wide range of antibiotics in different dosage forms, including Cefazolin Sodium injection solutions and Cefalotin Sodium injection solutions. Throughout its history, CSPC Pharmaceutical has received various awards and certifications that confirm the high quality of its products. In 2019, the company was honored as the "Best Innovative Pharmaceutical Firm" at the Asia-Pacific Biotech Industry Awards. Furthermore, CSPC Pharmaceutical has obtained the ISO 9001:2015 Quality Management System certificate, and its products are approved by the US FDA, the European Medicines Agency, and the National Medical Products Administration in China. Overall, CSPC Pharmaceutical is an important player in the Chinese pharmaceutical market, offering a wide product range and increasing the level of innovation through research and development. With its continuous growth and efforts towards quality and innovation, CSPC Pharmaceutical will continue to play a significant role in the global healthcare market. CSPC Pharmaceutical Group is one of the most popular companies on Eulerpool.com.

CSPC Pharmaceutical Group SWOT Analysis

Strengths

CSPC Pharmaceutical Group Ltd has several key strengths that contribute to its success in the pharmaceutical industry. Firstly, the company has a strong portfolio of high-quality and innovative products, which have gained significant market share both domestically and internationally.

Additionally, CSPC Pharmaceutical Group Ltd has established strong relationships with healthcare providers, distributors, and key stakeholders in the industry. This allows the company to efficiently market and distribute its products and expand its customer base.

Weaknesses

Despite its successes, CSPC Pharmaceutical Group Ltd faces a few weaknesses that it should address in order to maintain its competitive edge. One weakness is its heavy reliance on a limited number of blockbuster drugs for a significant portion of its revenue. This exposes the company to potential risks if these drugs face regulatory issues or competition from generic alternatives.

Additionally, CSPC Pharmaceutical Group Ltd operates mainly in the Chinese market, which makes it vulnerable to regulatory changes and economic fluctuations specific to that region. Expanding its presence in other international markets could help mitigate this weakness.

Opportunities

There are several opportunities that CSPC Pharmaceutical Group Ltd can leverage to drive growth and further strengthen its position in the industry. One opportunity is the increasing demand for healthcare products and services in emerging markets, such as China and other Asian countries. By capitalizing on this trend, the company can expand its customer base and increase its market share.

Additionally, advancements in technology and research present opportunities for CSPC Pharmaceutical Group Ltd to develop innovative therapies and drug delivery systems. Investing in research and development can help the company stay ahead of competitors and offer cutting-edge products to meet evolving customer needs.

Threats

CSPC Pharmaceutical Group Ltd faces certain threats that could impact its business operations and growth prospects. One significant threat is increasing competition from both domestic and international pharmaceutical companies. This can result in price pressures, loss of market share, and decreased profitability.

Moreover, regulatory changes and stringent approval processes for new drugs pose a threat to CSPC Pharmaceutical Group Ltd. Delays in obtaining necessary approvals can impact product launches and revenue generation.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

CSPC Pharmaceutical Group Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

CSPC Pharmaceutical Group historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

CSPC Pharmaceutical Group shares outstanding

The number of shares was CSPC Pharmaceutical Group in 2023 — This indicates how many shares 11.873 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue CSPC Pharmaceutical Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates CSPC Pharmaceutical Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of CSPC Pharmaceutical Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating CSPC Pharmaceutical Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

CSPC Pharmaceutical Group stock splits

In CSPC Pharmaceutical Group's history, there have been no stock splits.

CSPC Pharmaceutical Group dividend history and estimates

In 2023, CSPC Pharmaceutical Group paid a dividend amounting to 0.25 CNY. Dividend means that CSPC Pharmaceutical Group distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for CSPC Pharmaceutical Group provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify CSPC Pharmaceutical Group’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating CSPC Pharmaceutical Group's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

CSPC Pharmaceutical Group Dividend History

DateCSPC Pharmaceutical Group Dividend
2029e0.28 undefined
2028e0.28 undefined
2027e0.28 undefined
2026e0.28 undefined
2025e0.28 undefined
2024e0.28 undefined
20230.25 undefined
20220.2 undefined
20210.17 undefined
20200.14 undefined
20190.09 undefined
20180.08 undefined
20170.06 undefined
20160.06 undefined
20150.05 undefined
20140.04 undefined
20130.05 undefined
20110.12 undefined
20100.12 undefined
20090.1 undefined
20080.03 undefined
20040.04 undefined

CSPC Pharmaceutical Group dividend payout ratio

In 2023, CSPC Pharmaceutical Group had a payout ratio of 36.07%. The payout ratio indicates the percentage of the company's profits that CSPC Pharmaceutical Group distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for CSPC Pharmaceutical Group represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for CSPC Pharmaceutical Group could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate CSPC Pharmaceutical Group's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

CSPC Pharmaceutical Group Payout Ratio History

DateCSPC Pharmaceutical Group Payout ratio
2029e37.08 %
2028e37.17 %
2027e37.17 %
2026e36.89 %
2025e37.45 %
2024e37.15 %
202336.07 %
202239.13 %
202136.26 %
202032.83 %
201930.18 %
201830.39 %
201729.46 %
201635.09 %
201542.89 %
201421.81 %
201340.06 %
201236.07 %
201196.15 %
201029.07 %
200918.6 %
20084.73 %
200736.07 %
200636.07 %
200536.07 %
200421.45 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for CSPC Pharmaceutical Group.

CSPC Pharmaceutical Group latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20240.11 0.07  (-38.33 %)2024 Q3
6/30/20240.14 0.12  (-17.48 %)2024 Q2
3/31/20240.12 0.14  (12.96 %)2024 Q1
12/31/20230.17 0.12  (-32.02 %)2023 Q4
9/30/20230.13 0.13  (-4.19 %)2023 Q3
6/30/20230.13 0.13  (-1.22 %)2023 Q2
3/31/20230.13 0.13  (-1.96 %)2023 Q1
12/31/20220.13 0.14  (8.11 %)2022 Q4
9/30/20220.13 0.13  (0.16 %)2022 Q3
6/30/20220.25 0.13  (-46.7 %)2022 Q2
1
2
3
4
5
...
6

Eulerpool ESG Scorecard© for the CSPC Pharmaceutical Group stock

Eulerpool World ESG Rating (EESG©)

76/ 100

🌱 Environment

72

👫 Social

90

🏛️ Governance

66

Environment

Scope 1 - Direct Emissions
663,224
Scope 2 - Indirect emissions from purchased energy
418,037
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
1,081,261
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees48.16
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

CSPC Pharmaceutical Group shareholders

%
Name
Stocks
Change
Date
13.69366 % Cai (Dong Chen)1,596,619,2001,000,0009/9/2024
10.45353 % Massive Giant Group Ltd.1,218,834,47009/20/2024
6.25064 % Common Success International Ltd.728,796,313012/31/2023
3.87701 % UBS Asset Management (Hong Kong) Limited452,041,5047,326,63410/22/2024
2.42952 % The Vanguard Group, Inc.283,270,9551,060,0009/30/2024
2.20058 % First Sentier Investors (Hong Kong) Limited256,577,441-1,314,0009/30/2024
2.09061 % BlackRock Institutional Trust Company, N.A.243,755,858-6,486,4809/23/2024
1.99947 % Norges Bank Investment Management (NBIM)233,128,68462,596,0386/30/2024
1.37130 % Hang Seng Investment Management Ltd.159,887,095-5,685,0619/30/2024
1.23428 % Bosera Asset Management Co., Ltd.143,912,000730,0006/30/2024
1
2
3
4
5
...
10

CSPC Pharmaceutical Group Executives and Management Board

Mr. Dongchen Cai

(69)
CSPC Pharmaceutical Group Executive Chairman of the Board (since 1998)
Compensation 19.66 M

Mr. Cuilong Zhang

(54)
CSPC Pharmaceutical Group Executive Vice Chairman of the Board, Chief Executive Officer (since 2018)
Compensation 10.68 M

Mr. Chunlei Li

(46)
CSPC Pharmaceutical Group Executive Director (since 2017)
Compensation 7.68 M

Dr. Qingxi Wang

(57)
CSPC Pharmaceutical Group Executive Director (since 2018)
Compensation 6.77 M

Mr. Huaiyu Wang

(60)
CSPC Pharmaceutical Group Executive Director (since 2010)
Compensation 6.39 M
1
2
3
4

CSPC Pharmaceutical Group Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Verastem Stock
Verastem
SupplierCustomer0,390,640,26-0,240,660,46
UBS Group Stock
UBS Group
SupplierCustomer0,38-0,20-0,040,36-0,60-0,16
CSPC Innovation Pharmaceutical A Stock
CSPC Innovation Pharmaceutical A
SupplierCustomer0,36-0,490,750,640,08
Beijing ConST Instruments Technology A Stock
Beijing ConST Instruments Technology A
SupplierCustomer0,35-0,330,760,470,330,10
Shandong Pharm -A- Stock
Shandong Pharm -A-
SupplierCustomer0,17-0,540,760,220,180,05
I-MAB ADR Stock
I-MAB ADR
SupplierCustomer0,110,650,71-0,020,590,45
Xinlun New Materials A Stock
Xinlun New Materials A
SupplierCustomer0,06-0,470,760,260,190,22
Shanghai Medicilon A Stock
Shanghai Medicilon A
SupplierCustomer0,03-0,170,59-0,240,040,19
1

Most common questions regarding CSPC Pharmaceutical Group

What values and corporate philosophy does CSPC Pharmaceutical Group represent?

CSPC Pharmaceutical Group Ltd represents a strong commitment to innovation, quality, and patient care. With a focus on research and development, the company strives to bring innovative solutions and advanced therapies to improve healthcare outcomes. Their corporate philosophy revolves around integrity, ethical business practices, and sustainable growth. CSPC Pharmaceutical Group Ltd places importance on creating value for stakeholders, including patients, healthcare professionals, and investors. Through strategic collaborations and continuous investment in technology, they aim to enhance their product portfolio and expand their market presence globally. With their dedication to improving health and well-being, CSPC Pharmaceutical Group Ltd stands as a reliable and trusted pharmaceutical company.

In which countries and regions is CSPC Pharmaceutical Group primarily present?

CSPC Pharmaceutical Group Ltd is primarily present in China.

What significant milestones has the company CSPC Pharmaceutical Group achieved?

CSPC Pharmaceutical Group Ltd has achieved several significant milestones. It has successfully developed and commercialized a portfolio of high-quality and affordable generic drugs, contributing to improved healthcare accessibility and affordability. The company has also made significant advancements in research and development, with a strong focus on innovative drug formulations and technologies. Additionally, CSPC Pharmaceutical Group Ltd has established strategic partnerships for global expansion, increasing its presence in international markets. Through its commitment to innovation, quality, and partnerships, CSPC Pharmaceutical Group Ltd continues to deliver value to its stakeholders and make a positive impact in the pharmaceutical industry.

What is the history and background of the company CSPC Pharmaceutical Group?

CSPC Pharmaceutical Group Ltd, a leading Chinese pharmaceutical company, has a rich history and background. Established in 1997, the company has demonstrated remarkable growth and development over the years. It specializes in the research, development, manufacturing, and sale of innovative and high-quality pharmaceutical products. Leveraging its expertise in active pharmaceutical ingredients (APIs), finished dosage forms, and biopharmaceuticals, CSPC has established a strong presence both domestically and internationally. By prioritizing technological advancements, quality assurance, and customer satisfaction, CSPC has successfully built a solid reputation in the pharmaceutical industry. Continuously expanding its product portfolio and global reach, CSPC Pharmaceutical Group Ltd remains committed to the advancement of healthcare worldwide.

Who are the main competitors of CSPC Pharmaceutical Group in the market?

The main competitors of CSPC Pharmaceutical Group Ltd in the market include Shanghai Pharmaceuticals Holding Co., Ltd, Harbin Pharmaceutical Group Co., Ltd, and Jiangsu Hengrui Medicine Co., Ltd.

In which industries is CSPC Pharmaceutical Group primarily active?

CSPC Pharmaceutical Group Ltd is primarily active in the pharmaceutical industry.

What is the business model of CSPC Pharmaceutical Group?

The business model of CSPC Pharmaceutical Group Ltd focuses on research, development, manufacturing, and sales of pharmaceutical products. With a comprehensive portfolio, CSPC primarily operates in the fields of antibiotics, vitamins, and cardiovascular drugs. The company leverages its strong R&D capabilities to produce innovative and high-quality medicines that address various medical needs. By maintaining a vertically integrated business model, CSPC ensures control and efficiency throughout the entire production process, from raw material procurement to final product distribution. With a commitment to technological advancement and continuous improvement, CSPC Pharmaceutical Group Ltd strives to provide safe and effective healthcare solutions to patients worldwide.

What is the P/E ratio of CSPC Pharmaceutical Group 2024?

The CSPC Pharmaceutical Group P/E ratio is 9.14.

What is the P/S ratio of CSPC Pharmaceutical Group 2024?

The CSPC Pharmaceutical Group P/S ratio is 1.69.

What is the Quality Investing of CSPC Pharmaceutical Group?

The Quality Investing for CSPC Pharmaceutical Group is 10/10.

What is the revenue of CSPC Pharmaceutical Group 2024?

The expected CSPC Pharmaceutical Group revenue is 33.11 B CNY.

How high is the profit of CSPC Pharmaceutical Group 2024?

The expected CSPC Pharmaceutical Group profit is 6.13 B CNY.

What is the business model of CSPC Pharmaceutical Group

The CSPC Pharmaceutical Group Ltd is a leading global provider of pharmaceutical products and medications. With a wide portfolio of products and a comprehensive business model, the company has established itself as one of the key players in the industry. CSPC operates in various divisions that offer different products and services, including pharmaceutical manufacturing, distribution, research and development, and partnerships and acquisitions. The company offers a range of medications, including antibiotics, painkillers, anti-inflammatory drugs, and specialized products in areas such as cardiology, oncology, and gastroenterology. Through its extensive product range, research and development activities, and international distribution channels, CSPC is positioned to continue growing and expanding its presence globally.

What is the CSPC Pharmaceutical Group dividend?

CSPC Pharmaceutical Group pays a dividend of 0.2 CNY distributed over payouts per year.

How often does CSPC Pharmaceutical Group pay dividends?

The dividend cannot currently be calculated for CSPC Pharmaceutical Group or the company does not pay out a dividend.

What is the CSPC Pharmaceutical Group ISIN?

The ISIN of CSPC Pharmaceutical Group is HK1093012172.

What is the CSPC Pharmaceutical Group WKN?

The WKN of CSPC Pharmaceutical Group is 548183.

What is the CSPC Pharmaceutical Group ticker?

The ticker of CSPC Pharmaceutical Group is 1093.HK.

How much dividend does CSPC Pharmaceutical Group pay?

Over the past 12 months, CSPC Pharmaceutical Group paid a dividend of 0.25 CNY . This corresponds to a dividend yield of about 5.3 %. For the coming 12 months, CSPC Pharmaceutical Group is expected to pay a dividend of 0.28 CNY.

What is the dividend yield of CSPC Pharmaceutical Group?

The current dividend yield of CSPC Pharmaceutical Group is 5.3 %.

When does CSPC Pharmaceutical Group pay dividends?

CSPC Pharmaceutical Group pays a quarterly dividend. This is distributed in the months of June, July, November, December.

How secure is the dividend of CSPC Pharmaceutical Group?

CSPC Pharmaceutical Group paid dividends every year for the past 17 years.

What is the dividend of CSPC Pharmaceutical Group?

For the upcoming 12 months, dividends amounting to 0.28 CNY are expected. This corresponds to a dividend yield of 5.96 %.

In which sector is CSPC Pharmaceutical Group located?

CSPC Pharmaceutical Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von CSPC Pharmaceutical Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CSPC Pharmaceutical Group from 11/20/2024 amounting to 0.02 CNY, you needed to have the stock in your portfolio before the ex-date on 11/4/2024.

When did CSPC Pharmaceutical Group pay the last dividend?

The last dividend was paid out on 11/20/2024.

What was the dividend of CSPC Pharmaceutical Group in the year 2023?

In the year 2023, CSPC Pharmaceutical Group distributed 0.2 CNY as dividends.

In which currency does CSPC Pharmaceutical Group pay out the dividend?

The dividends of CSPC Pharmaceutical Group are distributed in CNY.

All fundamentals about CSPC Pharmaceutical Group

Our stock analysis for CSPC Pharmaceutical Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CSPC Pharmaceutical Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.